Fitzgerald Kevin Joseph — SEC Form 4 filings
SEC reporting owner CIK 1886431. 20 Form 4 filings on record with FilingPulse; latest filed 2026-04-09.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-02-26 to 2026-04-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 152 legs across 13 filings — 59,883 shares, $19,691,453 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: sale of 8,168 shares @ $449.00 ($3,667,432) in ALNYLAM PHARMACEUTICALS, INC., filed 2025-11-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | 15 | — | 152 legs · 59,883 sh · $19,691,453 | 20 |
| Ovid Therapeutics Inc. (OVID) | Director | 5 | — | — | 5 |
Form 4 filings — Fitzgerald Kevin Joseph
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-09 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 17,578 @ $2.56 | EDGAR |
| 2026-03-06 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 29 @ $319.03 · Sale (S): 28 @ $320.01 · Sale (S): 59 @ $320.81 · Sale (S): 79 @ $321.82 · Sale (S): 96 @ $323.01 · Sale (S): 210 @ $323.84 · +6 more | EDGAR |
| 2026-03-04 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,688 @ $0 · Sale (S): 47 @ $323.62 · Sale (S): 90 @ $324.65 · Sale (S): 258 @ $325.63 · Sale (S): 392 @ $326.81 · Sale (S): 329 @ $327.67 · +10 more | EDGAR |
| 2026-03-02 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 158 @ $0 | EDGAR |
| 2026-02-17 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,000 @ $0 · Sale (S): 1,959 @ $310.08 · Sale (S): 2,041 @ $331.96 | EDGAR |
| 2026-01-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,800 @ $0 · Sale (S): 39 @ $353.95 · Sale (S): 42 @ $355.16 · Sale (S): 41 @ $356.09 · Sale (S): 96 @ $357.17 · Sale (S): 123 @ $358.18 · +22 more | EDGAR |
| 2025-11-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 8,161 @ $119.13 · Sale (S): 8,168 @ $449 · Sale (S): 96 @ $450.09 · Sale (S): 129 @ $451.51 · Sale (S): 368 @ $455.24 · Sale (S): 364 @ $456.25 · +7 more | EDGAR |
| 2025-10-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 2,102 @ $0 · Grant/award (A): 2,851 @ $0 · Sale (S): 96 @ $446.53 · Sale (S): 47 @ $447.92 · Sale (S): 150 @ $448.77 · Sale (S): 207 @ $449.79 · +8 more | EDGAR |
| 2025-08-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 2,851 @ $0 · Sale (S): 39 @ $447.98 · Sale (S): 90 @ $449.92 · Sale (S): 39 @ $450.92 · Sale (S): 103 @ $451.99 · Sale (S): 329 @ $452.96 · +3 more | EDGAR |
| 2025-07-02 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 7,763 @ $0 | EDGAR |
| 2025-06-18 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,871 @ $0 · Sale (S): 204 @ $242.37 · Sale (S): 224 @ $243.36 · Sale (S): 151 @ $244.41 · Sale (S): 111 @ $245.26 · Sale (S): 45 @ $246.18 · +10 more | EDGAR |
| 2025-03-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 27 @ $236.51 · Sale (S): 21 @ $238.33 · Sale (S): 22 @ $239.18 · Sale (S): 48 @ $240.32 · Sale (S): 79 @ $241.51 · Sale (S): 187 @ $242.44 · +2 more | EDGAR |
| 2025-02-18 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 2,103 @ $0 · Sale (S): 145 @ $252.50 · Sale (S): 164 @ $253.37 · Sale (S): 110 @ $254.35 · Sale (S): 47 @ $255.56 · Sale (S): 53 @ $256.29 · +12 more | EDGAR |
| 2024-12-16 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,000 @ $0 · Sale (S): 26 @ $247.77 · Sale (S): 215 @ $249.60 · Sale (S): 318 @ $250.68 · Sale (S): 826 @ $251.42 · Sale (S): 84 @ $252.27 · +4 more | EDGAR |
| 2024-08-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 6,667 @ $97.72 · Option exercise (M): 14,058 @ $85 · Sale (S): 1,421 @ $268.66 · Sale (S): 9,662 @ $270.17 · Sale (S): 5,736 @ $271.32 · Sale (S): 3,913 @ $272.43 · +4 more | EDGAR |
| 2024-06-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 2,498 @ $0 · Sale (S): 45 @ $221.71 · Sale (S): 9 @ $224.17 · Sale (S): 13 @ $225.55 · Sale (S): 26 @ $226.82 · Sale (S): 96 @ $228.30 · +7 more | EDGAR |
| 2024-02-26 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1886431 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →